BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT™ injectable drug-eluting bone substitute products.
Company leadership attributes strong adoption to the efforts of its U.S. distribution partner, Zimmer Biomet, and strong surgeon demand in the EU for CERAMENT™|G (gentamicin) and CERAMENT™ V (vancomycin), indicated to promote bone healing in the management of infections.
CERAMENT G has been on the EU market since launch in 1Q13, while CERAMENT V entered EU launch in early 2Q15. The company signed its original distribution agreement with Biomet in 2012.
BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT™ injectable drug-eluting bone substitute products.
Company leadership attributes strong adoption to the efforts of its U.S. distribution partner, Zimmer Biomet, and strong surgeon demand in the EU for CERAMENT™|G (gentamicin) and CERAMENT™ V...
BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT™ injectable drug-eluting bone substitute products.
Company leadership attributes strong adoption to the efforts of its U.S. distribution partner, Zimmer Biomet, and strong surgeon demand in the EU for CERAMENT™|G (gentamicin) and CERAMENT™ V (vancomycin), indicated to promote bone healing in the management of infections.
CERAMENT G has been on the EU market since launch in 1Q13, while CERAMENT V entered EU launch in early 2Q15. The company signed its original distribution agreement with Biomet in 2012.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
